I am a breastfeeding mother and i want to know if it is safe to use EC 253-258-3? Is EC 253-258-3 safe for nursing mother and child? Does EC 253-258-3 extracts into breast milk? Does EC 253-258-3 has any long term or short term side effects on infants? Can EC 253-258-3 influence milk supply or can EC 253-258-3 decrease milk supply in lactating mothers?
- DrLact safety Score for EC 253-258-3 is 1 out of 8 which is considered Safe as per our analyses.
- A safety Score of 1 indicates that usage of EC 253-258-3 is mostly safe during lactation for breastfed baby.
- Our study of different scientific research also indicates that EC 253-258-3 does not cause any serious side effects in breastfeeding mothers.
- Most of scientific studies and research papers declaring usage of EC 253-258-3 safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
It is excreted into breast milk in non-significant amounts, without side-effects being reported in breastfed infants of treated mothers. Plasma levels among breastfed infants have been very low or undetectable. When used during pregnancy it has been associated to the Phenomenon of Reynaud in the nipple and a higher risk for neonatal hypoglycemia. The American Academy of Pediatrics rates it as commonly compatible with breastfeeding.
Because of the low levels of EC 253-258-3 in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in fullterm breastfed infants. No special precautions are required in most infants. However, other agents may be preferred while nursing a preterm infant.
One investigator reported that no adverse effects occurred in breastfed infants whose mothers were taking EC 253-258-3 in doses of 330 to 800 mg daily.[3] A 26-week premature infant weighing 640 g developed sinus bradycardia (80 to 90 bpm) and isolated atrial premature beats after nasogastric feeding with mother's pumped breastmilk was begun on day 8 of life. The mother was taking EC 253-258-3 300 mg twice daily by mouth for hypertension. Bradycardia and premature beats resolved within 24 hours of substitution of formula for breastmilk. No other causes for the bradycardia could be identified. One untimed sample of the mother's breastmilk contained 710 mcg/L of EC 253-258-3.[6] Although the authors estimated the infant's dose to be 100 mg/kg daily, a recalculation using their data indicates that the infant's dose was only 100 mcg/kg daily.
Intravenous EC 253-258-3 can increase serum prolactin in men and non-nursing women, although the increase is greater in women. Oral EC 253-258-3 does not increase serum prolactin.[7][8] The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed. A woman with a history of symptoms of Raynaud's phenomenon developed Raynaud's phenomenon of the nipples when treated for pregnancy-induced hypertension with EC 253-258-3 100 mg twice daily. She breastfed for 5 weeks, but nursing caused pain in her nipples. In a subsequent pregnancy, similar symptoms occurred during treatment with EC 253-258-3 100 mg twice daily. Discontinuing EC 253-258-3 eliminated the nipple pain in both instances.[9]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.